Insights into the molecular targets and emerging
pharmacotherapeutic interventions for nonalcoholic fatty liver
disease

J 2022

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

NEGI, Chander Kant, Pavel BABICA, Lola Murielle BAJARD ÉP.ESNER, Julie DOBROVOLNÁ, Giovanni TARANTINO et. al.

Základní údaje

Originální název

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

Autoři

NEGI, Chander Kant (356 Indie, domácí), Pavel BABICA (203 Česká republika, garant, domácí), Lola Murielle BAJARD ÉP.ESNER (250 Francie, domácí), Julie DOBROVOLNÁ (203 Česká republika, domácí) a Giovanni TARANTINO (380 Itálie)

Vydání

Metabolism: Clinical and Experimental, USA, W. B. Saunders Company, 2022, 0026-0495

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30202 Endocrinology and metabolism

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.800

Kód RIV

RIV/00216224:14310/22:00119691

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1016/j.metabol.2021.154925

UT WoS

000718929100007

Klíčová slova anglicky

Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Drug therapy; Clinical trials; Novel targets

Štítky

14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 3. 2023 21:18, Mgr. Michaela Hylsová, Ph.D.

Anotace

V originále

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. With no Food and Drug Administration approved drugs, current treatment options include dietary restrictions and lifestyle modification. NAFLD is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Hence, clinically various pharmacological approaches using existing drugs such as antidiabetic, anti-obesity, antioxidants, and cytoprotective agents have been considered in the management of NAFLD and nonalcoholic steatohepatitis (NASH). However, several pharmacological therapies aiming to alleviate NAFLD-NASH are currently being examined at various phases of clinical trials. Emerging data from these studies with drugs targeting diverse molecular mechanisms show promising outcomes. This review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms. In addition, we also discuss the importance and utility of new approach methodologies and regulatory perspectives for NAFLD-NASH drug development.

Návaznosti

EF17_043/0009632, projekt VaV

Název: CETOCOEN Excellence

GA19-19143S, projekt VaV

Název: 3-dimenzionální in vitro modely jater pro studium chronické hepatotoxicity a jaterních onemocnění indukovaných sinicovými toxiny.

Investor: Grantová agentura ČR, Jaterní 3D modely pro studium chronické hepatotoxicity a jaterních onemocnění indukovaných sinicovými toxiny

LM2018121, projekt VaV

Název: Výzkumná infrastruktura RECETOX (Akronym: RECETOX RI)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, RECETOX RI

Citovat

NEGI, Chander Kant, Pavel BABICA, Lola Murielle BAJARD ÉP.ESNER, Julie DOBROVOLNÁ a Giovanni TARANTINO. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental. USA: W. B. Saunders Company, 2022, roč. 126, January 2022, s. 1-18. ISSN 0026-0495. Dostupné z: https://dx.doi.org/10.1016/j.metabol.2021.154925.

@article{1838661,
   author = {Negi, Chander Kant and Babica, Pavel and Bajard ép.Esner, Lola Murielle and Dobrovolná, Julie and Tarantino, Giovanni},
   article_location = {USA},
   article_number = {January 2022},
   doi = {http://dx.doi.org/10.1016/j.metabol.2021.154925},
   keywords = {Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Drug therapy; Clinical trials; Novel targets},
   language = {eng},
   issn = {0026-0495},
   journal = {Metabolism: Clinical and Experimental},
   title = {Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease},
   url = {https://www.sciencedirect.com/science/article/pii/S0026049521002250?via%3Dihub},
   volume = {126},
   year = {2022}
}

TY  - JOUR
ID  - 1838661
AU  - Negi, Chander Kant - Babica, Pavel - Bajard ép.Esner, Lola Murielle - Dobrovolná, Julie - Tarantino, Giovanni
PY  - 2022
TI  - Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
JF  - Metabolism: Clinical and Experimental
VL  - 126
IS  - January 2022
SP  - 1-18
EP  - 1-18
PB  - W. B. Saunders Company
SN  - 00260495
KW  - Nonalcoholic fatty liver disease (NAFLD)
KW  - Nonalcoholic steatohepatitis (NASH)
KW  - Drug therapy
KW  - Clinical trials
KW  - Novel targets
UR  - https://www.sciencedirect.com/science/article/pii/S0026049521002250?via%3Dihub
N2  - Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. With no Food and Drug Administration approved drugs, current treatment options include dietary restrictions and lifestyle modification. NAFLD is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Hence, clinically various pharmacological approaches using existing drugs such as antidiabetic, anti-obesity, antioxidants, and cytoprotective agents have been considered in the management of NAFLD and nonalcoholic steatohepatitis (NASH). However, several pharmacological therapies aiming to alleviate NAFLD-NASH are currently being examined at various phases of clinical trials. Emerging data from these studies with drugs targeting diverse molecular mechanisms show promising outcomes. This review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms. In addition, we also discuss the importance and utility of new approach methodologies and regulatory perspectives for NAFLD-NASH drug development.
ER  -

NEGI, Chander Kant, Pavel BABICA, Lola Murielle BAJARD ÉP.ESNER, Julie DOBROVOLNÁ a Giovanni TARANTINO. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. \textit{Metabolism: Clinical and Experimental}. USA: W. B. Saunders Company, 2022, roč.~126, January 2022, s.~1-18. ISSN~0026-0495. Dostupné z: https://dx.doi.org/10.1016/j.metabol.2021.154925.

Podrobný výpis o publikaci